{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T12:13:38Z","timestamp":1753877618410,"version":"3.41.2"},"reference-count":10,"publisher":"Oxford University Press (OUP)","issue":"11-12","license":[{"start":{"date-parts":[[2021,12,28]],"date-time":"2021-12-28T00:00:00Z","timestamp":1640649600000},"content-version":"vor","delay-in-days":57,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000308","name":"Carnegie Corporation of New York","doi-asserted-by":"publisher","award":["B 8749.RO1"],"award-info":[{"award-number":["B 8749.RO1"]}],"id":[{"id":"10.13039\/100000308","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Discovery Foundation, South African Medical Association"},{"name":"South African Heart Association"},{"name":"University of the Witwatersrand Human Research Ethics Committee","award":["M150467"],"award-info":[{"award-number":["M150467"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,11,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:p>The risk of cardiovascular disease in patients with chronic inflammatory joint conditions is substantially increased compared to the general population. We present a case of a 27-year-old male with a chronic history of juvenile idiopathic arthritis (JIA) who presented with denovo acutely decompensated chronic heart failure. He had no traditional risk factors for atherosclerotic cardiovascular disease (ASCVD). However, during his workup for dilated cardiomyopathy, he was found to have extensive triple vessel disease on coronary artery angiography, and this was subsequently thought to be the most likely aetiology for the dilated cardiomyopathy despite being of young age. The chronic JIA was identified as the principal risk factor for the ischaemic cardiomyopathy. Clinicians treating patients with rheumatological conditions should routinely screen for ASCVD, despite the absence of traditional cardiovascular risk factors.<\/jats:p>","DOI":"10.1093\/omcr\/omab119","type":"journal-article","created":{"date-parts":[[2021,12,28]],"date-time":"2021-12-28T15:50:14Z","timestamp":1640706614000},"source":"Crossref","is-referenced-by-count":2,"title":["Extensive triple vessel coronary artery disease in a young male with juvenile idiopathic arthritis"],"prefix":"10.1093","volume":"2021","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7210-1447","authenticated-orcid":false,"given":"Nqoba","family":"Tsabedze","sequence":"first","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, School of Clinical Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mpoti","family":"Seboka","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, School of Clinical Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dineo","family":"Mpanya","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, School of Clinical Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed","family":"Solomon","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, School of Clinical Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,12,28]]},"reference":[{"key":"2021122815191470700_ref1","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1002\/art.37975","article-title":"Unresolved questions in rheumatology: motion for debate: the data support evidence-based management recommendations for cardiovascular disease in rheumatoid arthritis","volume":"65","author":"Solomon","year":"2013","journal-title":"Arthritis Rheum"},{"key":"2021122815191470700_ref2","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1136\/annrheumdis-2016-209775","article-title":"EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015\/2016 update","volume":"76","author":"Agca","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2021122815191470700_ref3","first-page":"390","article-title":"International league of associations for rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001","volume":"31","author":"Petty","year":"2004","journal-title":"J Rheumatol"},{"key":"2021122815191470700_ref4","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1002\/acr.20613","article-title":"Changes in vascular function and structure in juvenile idiopathic arthritis","volume":"63","author":"Vlahos","year":"2011","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2021122815191470700_ref5","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1007\/s100670170100","article-title":"Cytokine levels in serum of patients with juvenile rheumatoid arthritis","volume":"20","author":"Yilmaz","year":"2001","journal-title":"Clin Rheumatol"},{"key":"2021122815191470700_ref6","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1093\/rheumatology\/ket106","article-title":"Cardiovascular risk in juvenile idiopathic arthritis","volume":"52","author":"Coulson","year":"2013","journal-title":"Rheumatology"},{"key":"2021122815191470700_ref7","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1186\/ar4212","article-title":"Cardiovascular risk in pediatric-onset rheumatological diseases","volume":"15","author":"Barsalou","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"2021122815191470700_ref8","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s41572-019-0084-1","article-title":"Dilated cardiomyopathy","volume":"5","author":"Schultheiss","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"2021122815191470700_ref9","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1182\/blood.V68.5.1114.1114","article-title":"Cyclophosphamide cardiotoxicity: an analysis of dosing as a risk factor","volume":"68","author":"Goldberg","year":"1986","journal-title":"Blood"},{"key":"2021122815191470700_ref10","first-page":"263","article-title":"Cardiotoxicity of chemotherapeutic agents. Incidence, treatment and prevention. Drug safety: an international journal of medical toxicology and drug experience","volume-title":"Drug Safety","author":"Pai","year":"2000"}],"container-title":["Oxford Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/omcr\/article-pdf\/2021\/11-12\/omab119\/41940601\/omab119.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/omcr\/article-pdf\/2021\/11-12\/omab119\/41940601\/omab119.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,28]],"date-time":"2021-12-28T15:50:28Z","timestamp":1640706628000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/omcr\/article\/doi\/10.1093\/omcr\/omab119\/6485123"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,1]]},"references-count":10,"journal-issue":{"issue":"11-12","published-print":{"date-parts":[[2021,11,1]]}},"URL":"https:\/\/doi.org\/10.1093\/omcr\/omab119","relation":{},"ISSN":["2053-8855"],"issn-type":[{"type":"electronic","value":"2053-8855"}],"subject":[],"published-other":{"date-parts":[[2021,11]]},"published":{"date-parts":[[2021,11,1]]},"article-number":"omab119"}}